Cmed, an innovative technology-led oncology CRO, today announced it will be exhibiting at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois (June 3-5), and showing how encapsia® can help improve patient safety, study conduct and decision making in oncology clinical trials (Booth 23128).
Cmed has earned a strong reputation for successfully conducting oncology trials across all phases and in numerous cancer types, including breast, lung, prostate, colorectal and other solid cancers, and haematological malignancies.
Cmed, an innovative technology-led CRO, will present “Why eSource and what will it change? Accessing data in clinical trials” at the 4th Annual eSource Data in Clinical Investigations Conference in Philadelphia at 10.30am on Wednesday May 3rd, 2017.
Graham Belgrave, Cmed’s Chief Operations Officer, and Product Manager Jon Carter, will examine the principles of eSource and how it has the potential to be a real “game changer” for trial conduct and for study team roles.
Cmed Appoints New Global Head of Commercial Operations
03 Mar 2017
Cmed, an innovative technology-led CRO, announced today the appointment of David Holloway as its new Global Head of Commercial Operations. His appointment strengthens Cmed’s management team as it accelerates new developments and opportunities for encapsia®, the first App based new generation clinical data suite available which has already been proven and used to successfully complete studies.
In this role, Mr. Holloway will help drive the continued commercialization of encapsia®, providing leadership and strategic guidance.